Shattuck Labs, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Shattuck Labs, Inc. (STTK) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.89 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- Shattuck Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.75, a 302.54% increase year-over-year.
- Shattuck Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.18, a 88.13% decline year-over-year.
- Shattuck Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.94, a 178.43% increase year-over-year.
- Shattuck Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.57, a 51.10% decline year-over-year.
- Shattuck Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.28, a 82.34% decline from fiscal 2024.
- Shattuck Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $7.25, a 112.61% increase from fiscal 2023.
- Shattuck Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.41, a 39.96% decline from fiscal 2022.
- Shattuck Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $5.68, a 75.93% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.89 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $4.75 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.28 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $1.14 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.18 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $1.18 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $7.25 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $9.24 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $9.33 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $9.94 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $3.41 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $3.41 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $3.41 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $3.57 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $5.68 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $5.96 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $6.35 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $7.30 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $23.60 10-K · filed 2022-03-15 | |||
| 2021-03-31 | $39.15 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $13.34 10-K · filed 2021-03-16 | |||
| 2020-09-30 | $5.28 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |